{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:30:55Z","timestamp":1790670655530,"version":"4.1.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Drug-resistant tuberculosis (DR-TB) kills ~200,000 people every year. A contributing factor is the slow turnaround time (TAT) associated with drug susceptibility diagnostics. The prevailing gold standard for phenotypic drug susceptibility testing (pDST) takes at least two weeks. Here we show that growth-based pDST for slow-growing mycobacteria can be conducted in 12\u2009h. We use\n                    <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                    variant\n                    <jats:italic>bovis<\/jats:italic>\n                    Bacillus Calmette-Gu\u00e9rin (BCG) and\n                    <jats:italic>Mycobacterium smegmatis<\/jats:italic>\n                    as the mycobacterial pathogen models and expose them to antibiotics used in (multidrug-resistant) tuberculosis (TB) treatment regimens -\n                    <jats:italic>i.e<\/jats:italic>\n                    ., rifampicin (RIF), isoniazid (INH), ethambutol (EMB), linezolid (LZD), streptomycin (STR), bedaquiline (BDQ), and levofloxacin (LFX). The bacterial growth in a microfluidic chip is tracked by time-lapse phase-contrast microscopy. A deep neural network-based segmentation algorithm is used to quantify the growth rate and to determine how the strains responded to drug treatments. Most importantly, a panel of susceptible and resistant\n                    <jats:italic>M. bovis<\/jats:italic>\n                    BCG are tested at critical concentrations for INH, RIF, STR, and LFX. The susceptible strains could be identified in less than 12\u2009h. These findings are comparable to what we expect for pathogenic\n                    <jats:italic>M. tuberculosis<\/jats:italic>\n                    as they share 99.96% genetic identity.\n                  <\/jats:p>","DOI":"10.1038\/s41467-025-59736-9","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T15:06:20Z","timestamp":1746889580000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Phenotypic drug susceptibility testing for Mycobacterium tuberculosis variant bovis BCG in 12\u2009hours"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3440-8974","authenticated-orcid":false,"given":"Buu Minh","family":"Tran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6487-5803","authenticated-orcid":false,"given":"Anastasia","family":"Grip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5925-8669","authenticated-orcid":false,"given":"Praneeth","family":"Karempudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5522-1810","authenticated-orcid":false,"given":"Johan","family":"Elf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,10]]},"reference":[{"key":"59736_CR1","first-page":"E9","volume":"58","author":"I Barberis","year":"2017","unstructured":"Barberis, I., Bragazzi, N. L., Galluzzo, L. & Martini, M. The history of tuberculosis: from the first historical records to the isolation of Koch\u2019s bacillus. J. Prev. Med. Hyg. 58, E9\u2013E12 (2017).","journal-title":"J. Prev. Med. Hyg."},{"key":"59736_CR2","unstructured":"Geneva: World Health Organization. Global Tuberculosis Report. https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2024 (2024)."},{"key":"59736_CR3","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"CJL Murray","year":"2022","unstructured":"Murray, C. J. L. et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399, 629\u2013655 (2022).","journal-title":"Lancet"},{"key":"59736_CR4","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S2213-2600(14)70031-1","volume":"2","author":"K Dheda","year":"2014","unstructured":"Dheda, K. et al. Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respir. Med. 2, 321\u2013338 (2014).","journal-title":"Lancet Respir. Med"},{"key":"59736_CR5","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jinf.2023.06.014","volume":"87","author":"OS Pedersen","year":"2023","unstructured":"Pedersen, O. S. et al. Global treatment outcomes of extensively drug-resistant tuberculosis in adults: a systematic review and meta-analysis. J. Infect. 87, 177\u2013189 (2023).","journal-title":"J. Infect."},{"key":"59736_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40249-023-01107-x","volume":"12","author":"N Salari","year":"2023","unstructured":"Salari, N. et al. Global prevalence of drug-resistant tuberculosis: a systematic review and meta-analysis. Infect. Dis. Poverty 12, 1\u201312 (2023).","journal-title":"Infect. Dis. Poverty"},{"key":"59736_CR7","doi-asserted-by":"publisher","first-page":"a017863","DOI":"10.1101\/cshperspect.a017863","volume":"5","author":"KJ Seung","year":"2015","unstructured":"Seung, K. J., Keshavjee, S. & Rich, M. L. Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Cold Spring Harb. Perspect. Med. 5, a017863 (2015).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"59736_CR8","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1016\/S1473-3099(22)00875-1","volume":"23","author":"J Dom\u00ednguez","year":"2023","unstructured":"Dom\u00ednguez, J. et al. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet\/RESIST-TB consensus statement. Lancet Infect. Dis. 23, e122\u2013e137 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"59736_CR9","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/S1473-3099(21)00808-2","volume":"22","author":"AS Dean","year":"2022","unstructured":"Dean, A. S. et al. 25 years of surveillance of drug-resistant tuberculosis: achievements, challenges, and way forward. Lancet Infect. Dis. 22, e191\u2013e196 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"59736_CR10","doi-asserted-by":"publisher","first-page":"e0119332","DOI":"10.1371\/journal.pone.0119332","volume":"10","author":"K Chung-Delgado","year":"2015","unstructured":"Chung-Delgado, K., Guillen-Bravo, S., Revilla-Montag, A. & Bernabe-Ortiz, A. Mortality among MDR-TB cases: comparison with drug-susceptible tuberculosis and associated factors. PLoS One 10, e0119332 (2015).","journal-title":"PLoS One"},{"key":"59736_CR11","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1093\/jac\/dkx506","volume":"73","author":"N Dookie","year":"2018","unstructured":"Dookie, N., Rambaran, S., Padayatchi, N., Mahomed, S. & Naidoo, K. Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care. J. Antimicrob. Chemother. 73, 1138\u20131151 (2018).","journal-title":"J. Antimicrob. Chemother."},{"key":"59736_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-05967-2","volume":"21","author":"E Kizito","year":"2021","unstructured":"Kizito, E. et al. Risk factors for mortality among patients diagnosed with multi-drug resistant tuberculosis in Uganda- a case-control study. BMC Infect. Dis. 21, 292 (2021).","journal-title":"BMC Infect. Dis."},{"key":"59736_CR13","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ijid.2020.10.084","volume":"103","author":"R Diel","year":"2021","unstructured":"Diel, R., Sotgiu, G., Andres, S., Hillemann, D. & Maurer, F. P. Cost of multidrug resistant tuberculosis in Germany-an update. Int. J. Infect. Dis. 103, 102\u2013109 (2021).","journal-title":"Int. J. Infect. Dis."},{"key":"59736_CR14","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S1473-3099(18)30673-X","volume":"19","author":"K Z\u00fcrcher","year":"2019","unstructured":"Z\u00fcrcher, K. et al. Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries: a multicentre cohort study. Lancet Infect. Dis. 19, 298\u2013307 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"59736_CR15","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/S1473-3099(18)30742-4","volume":"19","author":"R Acquah","year":"2019","unstructured":"Acquah, R. & Furin, J. Universal regimens or universal access to drug susceptibility testing for tuberculosis? Lancet Infect. Dis. 19, 224\u2013225 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"59736_CR16","doi-asserted-by":"publisher","first-page":"2200166","DOI":"10.1183\/13993003.00166-2022","volume":"59","author":"Antimycobacterial Susceptibility Testing Group.","year":"2022","unstructured":"Antimycobacterial Susceptibility Testing Group. Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment. Eur. Respir. J. 59, 2200166 (2022).","journal-title":"Eur. Respir. J."},{"key":"59736_CR17","doi-asserted-by":"publisher","first-page":"e02314-20","DOI":"10.1128\/JCM.02314-20","volume":"59","author":"Y Cao","year":"2021","unstructured":"Cao, Y. et al. Xpert MTB\/XDR: a 10-Color reflex assay suitable for point-of-care settings to detect isoniazid, fluoroquinolone, and second-line-injectable-drug resistance directly from mycobacterium tuberculosis-positive sputum. J. Clin. Microbiol. 59, e02314-20 (2021).","journal-title":"J. Clin. Microbiol."},{"key":"59736_CR18","doi-asserted-by":"publisher","first-page":"210149","DOI":"10.1183\/20734735.0149-2021","volume":"18","author":"CM Gill","year":"2022","unstructured":"Gill, C. M., Dolan, L., Piggott, L. M. & McLaughlin, A. M. New developments in tuberculosis diagnosis and treatment. Breathe (Sheff.) 18, 210149 (2022).","journal-title":"Breathe (Sheff.)"},{"key":"59736_CR19","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1056\/NEJMc1215305","volume":"369","author":"CU K\u00f6ser","year":"2013","unstructured":"K\u00f6ser, C. U. et al. Whole-genome sequencing for rapid susceptibility testing of M. tuberculosis. N. Engl. J. Med. 369, 290\u2013292 2013).","journal-title":"N. Engl. J. Med."},{"key":"59736_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.cmi.2016.09.008","volume":"23","author":"D Papaventsis","year":"2017","unstructured":"Papaventsis, D. et al. Whole genome sequencing of Mycobacterium tuberculosis for detection of drug resistance: a systematic review. Clin. Microbiol. Infect. 23, 61\u201368 (2017).","journal-title":"Clin. Microbiol. Infect."},{"key":"59736_CR21","doi-asserted-by":"publisher","first-page":"870768","DOI":"10.3389\/fimmu.2022.870768","volume":"13","author":"KA Yusoof","year":"2022","unstructured":"Yusoof, K. A. et al. Tuberculosis phenotypic and genotypic drug susceptibility testing and immunodiagnostics: a review. Front. Immunol. 13, 870768 (2022).","journal-title":"Front. Immunol."},{"key":"59736_CR22","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1136\/thorax-2023-220202","volume":"79","author":"SN Danchuk","year":"2024","unstructured":"Danchuk, S. N. et al. Challenging the gold standard: the limitations of molecular assays for detection of Mycobacterium tuberculosis heteroresistance. Thorax 79, 670\u2013675 (2024).","journal-title":"Thorax"},{"key":"59736_CR23","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1056\/NEJMoa1800474","volume":"379","author":"The CRyPTIC Consortium and the 100,000 Genomes Project.","year":"2018","unstructured":"The CRyPTIC Consortium and the 100,000 Genomes Project. Prediction of susceptibility to first-line tuberculosis drugs by DNA Sequencing. N. Engl. J. Med. 379, 1403\u20131415 (2018).","journal-title":"N. Engl. J. Med."},{"key":"59736_CR24","doi-asserted-by":"publisher","first-page":"e01480-17","DOI":"10.1128\/JCM.01480-17","volume":"56","author":"TP Quan","year":"2018","unstructured":"Quan, T. P. et al. Evaluation of whole-genome sequencing for Mycobacterial species identification and drug susceptibility testing in a clinical setting: a large-scale prospective assessment of performance against line probe assays and phenotyping. J. Clin. Microbiol. 56, e01480-17 (2018).","journal-title":"J. Clin. Microbiol."},{"key":"59736_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-29652-3","volume":"13","author":"Y-X Xiao","year":"2023","unstructured":"Xiao, Y.-X., Liu, K.-H., Lin, W.-H., Chan, T.-H. & Jou, R. Whole-genome sequencing-based analyses of drug-resistant Mycobacterium tuberculosis from Taiwan. Sci. Rep. 13, 2540 (2023).","journal-title":"Sci. Rep."},{"key":"59736_CR26","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.cmi.2016.11.012","volume":"23","author":"MJ Ellington","year":"2017","unstructured":"Ellington, M. J. et al. The role of whole genome sequencing in antimicrobial susceptibility testing of bacteria: report from the EUCAST Subcommittee. Clin. Microbiol. Infect. 23, 2\u201322 (2017).","journal-title":"Clin. Microbiol. Infect."},{"key":"59736_CR27","doi-asserted-by":"publisher","first-page":"102341","DOI":"10.1016\/j.tube.2023.102341","volume":"140","author":"J Zhu","year":"2023","unstructured":"Zhu, J. et al. Acquired drug resistance during the turnaround time for drug susceptibility testing impacts outcome of tuberculosis. Tuberculosis 140, 102341 (2023).","journal-title":"Tuberculosis"},{"key":"59736_CR28","doi-asserted-by":"publisher","first-page":"105151","DOI":"10.1016\/j.micinf.2023.105151","volume":"25","author":"A Vocat","year":"2023","unstructured":"Vocat, A. et al. Nanomotion technology in combination with machine learning: a new approach for a rapid antibiotic susceptibility test for Mycobacterium tuberculosis. Microbes Infect. 25, 105151 (2023).","journal-title":"Microbes Infect."},{"key":"59736_CR29","doi-asserted-by":"publisher","first-page":"9170","DOI":"10.1073\/pnas.1708558114","volume":"114","author":"\u00d6 Baltekin","year":"2017","unstructured":"Baltekin, \u00d6., Boucharin, A., Tano, E., Andersson, D. I. & Elf, J. Antibiotic susceptibility testing in less than 30 min using direct single-cell imaging. Proc. Natl Acad. Sci. USA. 114, 9170\u20139175 (2017).","journal-title":"Proc. Natl Acad. Sci. USA."},{"key":"59736_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-022-33659-1","volume":"13","author":"V Kandavalli","year":"2022","unstructured":"Kandavalli, V., Karempudi, P., Larsson, J. & Elf, J. Rapid antibiotic susceptibility testing and species identification for mixed samples. Nat. Commun. 13, 1\u20138 (2022).","journal-title":"Nat. Commun."},{"key":"59736_CR31","unstructured":"Gallagher, J. \u00a38m Longitude prize won for tackling superbug rise. BBC (12 June 2024) (2024)."},{"key":"59736_CR32","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1126\/science.1216166","volume":"335","author":"BB Aldridge","year":"2012","unstructured":"Aldridge, B. B. et al. Asymmetry and aging of mycobacterial cells lead to variable growth and antibiotic susceptibility. Science 335, 100\u2013104 (2012).","journal-title":"Science"},{"key":"59736_CR33","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.1229858","volume":"339","author":"Y Wakamoto","year":"2013","unstructured":"Wakamoto, Y. et al. Dynamic persistence of antibiotic-stressed mycobacteria. Science 339, 91\u201395 (2013).","journal-title":"Science"},{"key":"59736_CR34","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s42003-020-0915-3","volume":"3","author":"VO Baron","year":"2020","unstructured":"Baron, V. O. et al. Real-time monitoring of live mycobacteria with a microfluidic acoustic-Raman platform. Commun. Biol. 3, 236 (2020).","journal-title":"Commun. Biol."},{"key":"59736_CR35","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41378-021-00262-1","volume":"7","author":"H Wang","year":"2021","unstructured":"Wang, H., Conover, G. M., Han, S.-I., Sacchettini, J. C. & Han, A. Development of single-cell-level microfluidic technology for long-term growth visualization of living cultures of Mycobacterium smegmatis. Microsyst. Nanoeng. 7, 37 (2021).","journal-title":"Microsyst. Nanoeng."},{"key":"59736_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-24175-9","volume":"12","author":"M Mistretta","year":"2022","unstructured":"Mistretta, M., Gangneux, N. & Manina, G. Microfluidic dose-response platform to track the dynamics of drug response in single mycobacterial cells. Sci. Rep. 12, 19578 (2022).","journal-title":"Sci. Rep."},{"key":"59736_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48269-2","volume":"15","author":"M Mistretta","year":"2024","unstructured":"Mistretta, M. et al. Dynamic microfluidic single-cell screening identifies pheno-tuning compounds to potentiate tuberculosis therapy. Nat. Commun. 15, 4175 (2024).","journal-title":"Nat. Commun."},{"key":"59736_CR38","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1038\/s41564-024-01846-z","volume":"9","author":"ES Chung","year":"2024","unstructured":"Chung, E. S., Kar, P., Kamkaew, M., Amir, A. & Aldridge, B. B. Single-cell imaging of the Mycobacterium tuberculosis cell cycle reveals linear and heterogenous growth. Nat. Microbiol. 9, 3332\u20133344 (2024).","journal-title":"Nat. Microbiol."},{"key":"59736_CR39","doi-asserted-by":"publisher","first-page":"267ra174","DOI":"10.1126\/scitranslmed.3009650","volume":"6","author":"J Choi","year":"2014","unstructured":"Choi, J. et al. A rapid antimicrobial susceptibility test based on single-cell morphological analysis. Sci. Transl. Med. 6, 267ra174 (2014).","journal-title":"Sci. Transl. Med."},{"key":"59736_CR40","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1007\/s00253-015-7210-0","volume":"100","author":"J Choi","year":"2016","unstructured":"Choi, J. et al. Rapid drug susceptibility test of Mycobacterium tuberculosis using microscopic time-lapse imaging in an agarose matrix. Appl. Microbiol. Biotechnol. 100, 2355\u20132365 (2016).","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"59736_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-26419-z","volume":"8","author":"Y-G Jung","year":"2018","unstructured":"Jung, Y.-G. et al. A rapid culture system uninfluenced by an inoculum effect increases reliability and convenience for drug susceptibility testing of Mycobacterium tuberculosis. Sci. Rep. 8, 8651 (2018).","journal-title":"Sci. Rep."},{"key":"59736_CR42","doi-asserted-by":"publisher","first-page":"6059","DOI":"10.1007\/s00253-021-11446-0","volume":"105","author":"H Kim","year":"2021","unstructured":"Kim, H. et al. Performance of quantamatrix microfluidic agarose channel system integrated with mycobacteria growth indicator tube liquid culture. Appl. Microbiol. Biotechnol. 105, 6059\u20136072 (2021).","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"59736_CR43","doi-asserted-by":"publisher","first-page":"e2216216120","DOI":"10.1073\/pnas.2216216120","volume":"120","author":"G Brandis","year":"2023","unstructured":"Brandis, G., Larsson, J. & Elf, J. Antibiotic perseverance increases the risk of resistance development. Proc. Natl Acad. Sci. USA. 120, e2216216120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA."},{"key":"59736_CR44","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1038\/s41592-022-01639-4","volume":"19","author":"KJ Cutler","year":"2022","unstructured":"Cutler, K. J. et al. Omnipose: a high-precision morphology-independent solution for bacterial cell segmentation. Nat. Methods 19, 1438\u20131448 (2022).","journal-title":"Nat. Methods"},{"key":"59736_CR45","doi-asserted-by":"crossref","unstructured":"Chung, E.S., Kar, P., Kamkaew, M. et al. Single-cell imaging of the Mycobacterium tuberculosis cell cycle reveals linear and heterogenous growth. Nat Microbiol. 9, 3332\u20133344 (2024).","DOI":"10.1038\/s41564-024-01846-z"},{"key":"59736_CR46","doi-asserted-by":"publisher","unstructured":"Ronneberger, O., Fischer, P., Brox, T. U-Net: Convolutional Networks for Biomedical Image Segmentation. In Medical Image Computing and Computer-Assisted Intervention \u2013 MICCAI 2015. MICCAI 2015. Lecture Notes in Computer Science() (eds Navab, N., Hornegger, J., Wells, W. & Frangi, A.) Vol 9351. (Springer, Cham, 2015). https:\/\/doi.org\/10.1007\/978-3-319-24574-4_28.","DOI":"10.1007\/978-3-319-24574-4_28"},{"key":"59736_CR47","unstructured":"N\u00fa\u00f1ez-Fern\u00e1ndez, D., Ballan, L., Jim\u00e9nez-Avalos, G., Coronel, J. & Zimic, M. Automatic semantic segmentation for prediction of tuberculosis using lens-free microscopy images. CoRR abs\/2007.02482 (2020)."},{"key":"59736_CR48","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1021\/jacsau.1c00173","volume":"1","author":"M Kamariza","year":"2021","unstructured":"Kamariza, M. et al. Toward point-of-care detection of Mycobacterium tuberculosis: a brighter solvatochromic probe detects mycobacteria within minutes. JACS Au 1, 1368\u20131379 (2021).","journal-title":"JACS Au"},{"key":"59736_CR49","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1109\/TMI.2017.2677499","volume":"36","author":"N Kumar","year":"2017","unstructured":"Kumar, N. et al. A dataset and a technique for generalized nuclear segmentation for computational pathology. IEEE Trans. Med. Imaging 36, 1550\u20131560 (2017).","journal-title":"IEEE Trans. Med. Imaging"},{"key":"59736_CR50","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1128\/AAC.46.8.2720-2722.2002","volume":"46","author":"J-C Palomino","year":"2002","unstructured":"Palomino, J.-C. et al. Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 46, 2720\u20132722 (2002).","journal-title":"Antimicrob. Agents Chemother."},{"key":"59736_CR51","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1128\/JCM.36.2.362-366.1998","volume":"36","author":"SG Franzblau","year":"1998","unstructured":"Franzblau, S. G. et al. Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay. J. Clin. Microbiol. 36, 362\u2013366 (1998).","journal-title":"J. Clin. Microbiol."},{"key":"59736_CR52","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/j.cmi.2020.07.036","volume":"26","author":"T Sch\u00f6n","year":"2020","unstructured":"Sch\u00f6n, T. et al. Antimicrobial susceptibility testing of Mycobacterium tuberculosis complex isolates - the EUCAST broth microdilution reference method for MIC determination. Clin. Microbiol. Infect. 26, 1488\u20131492 (2020).","journal-title":"Clin. Microbiol. Infect."},{"key":"59736_CR53","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3389\/fmicb.2018.00514","volume":"9","author":"MM Logsdon","year":"2018","unstructured":"Logsdon, M. M. & Aldridge, B. B. Stable regulation of cell cycle events in mycobacteria: insights from inherently heterogeneous bacterial populations. Front. Microbiol. 9, 514 (2018).","journal-title":"Front. Microbiol."},{"key":"59736_CR54","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1016\/j.cub.2017.09.046","volume":"27","author":"MM Logsdon","year":"2017","unstructured":"Logsdon, M. M. et al. A parallel adder coordinates mycobacterial cell-cycle progression and cell-size homeostasis in the context of asymmetric growth and organization. Curr. Biol. 27, 3367\u20133374 (2017).","journal-title":"Curr. Biol."},{"key":"59736_CR55","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1111\/j.1365-2958.2005.04878.x","volume":"58","author":"J Stephan","year":"2005","unstructured":"Stephan, J. et al. The growth rate of Mycobacterium smegmatis depends on sufficient porin-mediated influx of nutrients. Mol. Microbiol. 58, 714\u2013730 (2005).","journal-title":"Mol. Microbiol."},{"key":"59736_CR56","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/femsre\/fux011","volume":"41","author":"SM Gygli","year":"2017","unstructured":"Gygli, S. M., Borrell, S., Trauner, A. & Gagneux, S. Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives. FEMS Microbiol. Rev. 41, 354\u2013373 (2017).","journal-title":"FEMS Microbiol. Rev."},{"key":"59736_CR57","doi-asserted-by":"publisher","first-page":"O361","DOI":"10.1111\/1469-0691.12415","volume":"20","author":"CC Naidoo","year":"2014","unstructured":"Naidoo, C. C. & Pillay, M. Increased in vitro fitness of multi- and extensively drug-resistant F15\/LAM4\/KZN strains of Mycobacterium tuberculosis. Clin. Microbiol. Infect. 20, O361\u2013O369 (2014).","journal-title":"Clin. Microbiol. Infect."},{"key":"59736_CR58","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.tube.2012.11.004","volume":"93","author":"FS Spies","year":"2013","unstructured":"Spies, F. S. et al. Biological cost in Mycobacterium tuberculosis with mutations in the rpsL, rrs, rpoB, and katG genes. Tuberculosis 93, 150\u2013154 (2013).","journal-title":"Tuberculosis"},{"key":"59736_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-94645-z","volume":"11","author":"T Maeda","year":"2021","unstructured":"Maeda, T., Kawada, M., Sakata, N., Kotani, H. & Furusawa, C. Laboratory evolution of Mycobacterium on agar plates for analysis of resistance acquisition and drug sensitivity profiles. Sci. Rep. 11, 15136 (2021).","journal-title":"Sci. Rep."},{"key":"59736_CR60","doi-asserted-by":"publisher","first-page":"384.e5","DOI":"10.1016\/j.cmi.2019.10.033","volume":"26","author":"SN Danchuk","year":"2020","unstructured":"Danchuk, S. N., McIntosh, F., Jamieson, F. B., May, K. & Behr, M. A. Bacillus Calmette-Gu\u00e9rin strains with defined resistance mutations: a new tool for tuberculosis laboratory quality control. Clin. Microbiol. Infect. 26, 384.e5\u2013384.e8 (2020).","journal-title":"Clin. Microbiol. Infect."},{"key":"59736_CR61","unstructured":"Geneva: World Health Organization. Technical Report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis. https:\/\/www.who.int\/publications\/i\/item\/WHO-CDS-TB-2018.5 (2018)."},{"key":"59736_CR62","unstructured":"Geneva: World Health Organization. Technical Report on critical concentrations for drug susceptibility testing of isoniazid and the rifamycins (rifampicin, rifabutin and rifapentine). https:\/\/www.who.int\/publications\/i\/item\/9789240017283 (2021)."},{"key":"59736_CR63","unstructured":"Geneva: World Health Organization. Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis. https:\/\/www.who.int\/publications\/i\/item\/9789241514842 (2018)."},{"key":"59736_CR64","unstructured":"M24 Ed3. Clinical & Laboratory Standards Institute https:\/\/clsi.org\/standards\/products\/microbiology\/documents\/m24\/ (2018)."},{"key":"59736_CR65","unstructured":"Geneva: World Health Organization. WHO consolidated guidelines on tuberculosis: module 3: diagnosis: rapid diagnostics for tuberculosis detection, 2021 update. https:\/\/www.who.int\/publications\/i\/item\/9789240029415 (2021)."},{"key":"59736_CR66","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1128\/JCM.38.3.1203-1208.2000","volume":"38","author":"Luz Caviedes","year":"2000","unstructured":"Caviedes, Luz. et al. Rapid, efficient detection and drug susceptibility testing of Mycobacterium tuberculosis in sputum by microscopic observation of broth cultures. J. Clin. Microbiol. 38, 1203\u20131208 (2000).","journal-title":"J. Clin. Microbiol."},{"key":"59736_CR67","doi-asserted-by":"publisher","first-page":"4432","DOI":"10.1128\/JCM.42.10.4432-4437.2004","volume":"42","author":"DAJ Moore","year":"2004","unstructured":"Moore, D. A. J. et al. Microscopic observation drug susceptibility assay, a rapid, reliable diagnostic test for multidrug-resistant tuberculosis suitable for use in resource-poor settings. J. Clin. Microbiol. 42, 4432\u20134437 (2004).","journal-title":"J. Clin. Microbiol."},{"key":"59736_CR68","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1056\/NEJMoa055524","volume":"355","author":"DAJ Moore","year":"2006","unstructured":"Moore, D. A. J. et al. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N. Engl. J. Med. 355, 1539\u20131550 (2006).","journal-title":"N. Engl. J. Med."},{"key":"59736_CR69","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.14440\/jbm.2014.36","volume":"1","author":"AD Edelstein","year":"2014","unstructured":"Edelstein, A. D. et al. Advanced methods of microscope control using \u03bcManager software. J. Biol. Methods 1, e10 (2014).","journal-title":"J. Biol. Methods"},{"key":"59736_CR70","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41592-019-0629-y","volume":"17","author":"D Camsund","year":"2020","unstructured":"Camsund, D. et al. Time-resolved imaging-based CRISPRi screening. Nat. Methods 17, 86\u201392 (2020).","journal-title":"Nat. Methods"},{"key":"59736_CR71","doi-asserted-by":"publisher","unstructured":"Tran, B. M., Larsson, J., Grip, A., Karempudi, P. & Elf, J. Microscopy data, analysis code, and segmentation models for Phenotypic drug susceptibility testing for Mycobacterium tuberculosis variant bovis BCG in 12-hour. Uppsala University. Dataset. https:\/\/doi.org\/10.17044\/scilifelab.26927146 (2025).","DOI":"10.17044\/scilifelab.26927146"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59736-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59736-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59736-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T16:03:26Z","timestamp":1746893006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59736-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,10]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["59736"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-59736-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5052218\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,10]]},"assertion":[{"value":"4 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.E. has patented the method (US10,041,104B) and founded Astrego Diagnostics, but he has no current association with that company. No current company is associated with this work, but there may be in the future. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4366"}}